

# **OXFORD-SOMALOGIC PARTNERSHIP**

## **INAUGURAL MEETING**

**Tuesday 26<sup>th</sup> - Friday 29<sup>th</sup>  
January 2016**

**Kennedy Institute of Rheumatology  
Roosevelt Drive  
Headington  
OXFORD  
OX3 7LD**

**Contact: [Philippa.wells@kennedy.ox.ac.uk](mailto:Philippa.wells@kennedy.ox.ac.uk)**

**Names in red have confirmed - Purple not yet confirmed**

# OXFORD-SOMALOGIC PARTNERSHIP

EVENT 1: Tuesday January 26<sup>th</sup> 2016 - 10am

KENNEDY INSTITUTE SEMINAR ROOM

## INTRODUCTION TO SOMALOGIC, SOMAMER REAGENTS AND SOMASCAN DISCOVERY ASSAY

Chairs: **Simon Lovestone** and **Marc Feldmann**

- the idea behind the Oxford-SomaLogic “Crucible”

- a. **Larry Gold** (Founder, Chairman)  
SomaLogic’s Vision and Mission: The Wellness Chip
- b. **Byron Hewett** (Chief Executive Officer)  
The “Crucible” and SomaLogic’s Commitment to Innovation with The Oxford Community
- c. **Steve Williams** (Chief Medical Officer)  
The SOMAscan Assay as a powerful diagnostic platform for uncovering new biology, discovering useful biomarkers, and transforming healthcare
- d. **Nebojsa Janjic** (Chief Science Officer)  
What makes Somamer reagents unique?
- e. **Mark Messenbaugh** (Executive Director, Corporate Strategy & Development),  
**Evan King** (Executive Director, Commercial Operations)  
– maybe with **Richard Liwicki** or **Maxine Allen**?  
How will we work together? Describing the agreements in place to facilitate discovery and partnership with SomaLogic

f. **Simon Lovestone & colleague**

View from a User: new discoveries are possible

g. **Elio Riboli** (Imperial College)

EPIC (European Prospective investigation into Cancer)

Large sample collections as discover engines for new diagnostics to enable early treatment or eventually prevention

#### PANEL DISCUSSION

Chairs: **Marc Feldmann/Larry Gold**

All the above

*1.00 - Lunch in Kennedy Foyer*

**HAVE YOU GOT AN IDEA WHICH COULD NEED SOMASCAN?  
Make an appointment!**

**Please contact : [Philippa.wells@kennedy.ox.ac.uk](mailto:Philippa.wells@kennedy.ox.ac.uk)**

# SMALLER DISCUSSION GROUPS

## OXFORD-SOMALOGIC PARTNERSHIP

WORKSHOP 1: Tuesday January 26<sup>th</sup> 2016 - 2-4.30pm

KENNEDY INSTITUTE BOARD ROOM

### 1. HOW TO OPTIMIZE HUMAN IMMUNE MONITORING

#### From Somalogic:

<b>Steve Williams</b>	Chief Medical Officer
<b>Larry Gold</b>	Founder, Chairman of the Board of Directors
<b>Nebojsa Janjic</b>	Chief Science Officer
<b>Mark Messenbaugh</b>	Exec Director, Corporate Strategy & Development
<b>Byron Hewett</b>	Chief Executive Officer

#### Attendees from Oxford:

<b>Paul Klenerman</b>	BRC, Director Translational Gastro
<b>Fiona Powrie</b>	Director, Kennedy Institute, Immunologist
<b>Simon Travis</b>	IBD Clinician
<b>Paul Bowness</b>	Ankylosing Spondylitis Clinician, Immunologist
<b>Enzo Cerundolo</b>	Cancer Immunology
<b>Katya Simon</b>	Immunology, Monitoring
<b>Marc Feldmann</b>	Immunology

#### Plus others interested:

**Andrew Pollard** (Childhood vaccines)  
**Holm Uhlig**  
**Ellie Barnes** (Liver Disease)  
**Ian Pavord** (Allergy)  
**Graham Ogg** (Allergy)  
**Kathryn Wood** (Transplants)  
**Georg Hollander** (Paediatrics)  
**Adrian Hill** (Vaccines)

# OXFORD-SOMALOGIC PARTNERSHIP

WORKSHOP 2: Tuesday January 26<sup>th</sup> 2016 - 4.30-6.30pm

KENNEDY INSTITUTE BOARD ROOM

## 2. HOW CAN SOMAMER REAGENTS AND SOMASCAN ENABLE DRUG TARGET DISCOVERY & VALIDATION?

CHAIRS: **Chas Bountra** and **Steve Williams**

From Somalogic:

<b>Steve Williams</b>	Chief Medical Officer
<b>Larry Gold</b>	Founder, Chairman of the Board of Directors
<b>Nebojsa Janjic</b>	Chief Science Officer
<b>Mark Messenbaugh</b>	Exec Director, Corporate Strategy & Development
<b>Byron Hewett</b>	Chief Executive Officer

Attendees from Oxford:

<b>Chas Bountra</b>	Structural Genomics Consortium
<b>Peter Ratcliffe</b>	
<b>Simon Lovestone</b>	

Plus other attendees:

From TDI / DDI –

**John Davis** (CSO DDI)  
**Stephen Wren** (DDI)  
**Paul Brennan** (Chemistry TDI)  
**Daniel Ebner** (Screens TDI)  
**Caleb Webber** (Informatics)  
**Nicola Burgess-Brown** (protein production SGC)  
**Benedikt Kessler** (proteomics TDI)

# OXFORD-SOMALOGIC PARTNERSHIP

WORKSHOP 3: Wednesday January 27<sup>th</sup> 2016 - 9.00-11.00??

KENNEDY INSTITUTE BOARD ROOM

## 3. HOW CAN PROTEOMIC PROFILING OF DISEASE TISSUES AND BLOOD UNCOVER NEW DISEASE BIOLOGY, DRUG TARGETS & BIOMARKERS FOR DISEASE?

### From Somalogic:

<b>Steve Williams</b>	Chief Medical Officer
<b>Larry Gold</b>	Founder, Chairman of the Board of Directors
<b>Nebojsa Janjic</b>	Chief Science Officer
<b>Mark Messenbaugh</b>	Exec Director, Corporate Strategy & Development
<b>Byron Hewett</b>	Chief Executive Officer

### Attendees from Oxford:

<b>Claudia Monaco</b>	Atherosclerosis, Kennedy Institute
<b>Keith Channon</b>	Atherosclerosis, Head BRC
<b>Marc Feldmann/</b>	
<b>Fiona McCann</b>	Arthritis
<b>Tonia Vincent</b>	Osteoarthritis
<b>Jagdeep Nanchahal/</b>	
<b>Lynn Williams</b>	Fibrosis
<b>Anna Schuh</b>	Cancer
<b>Gillies McKenna</b>	Cancer
<b>Simon Lovestone</b>	Neurodegeneration
<b>Zam Cader/</b>	
<b>Richard Wade Martins/</b>	
<b>Jessica Ash/</b>	
<b>Benjamine Liu</b>	
<b>Olaf Osange/</b>	
<b>Kevin Talbot</b>	

Plus others interested:

# OXFORD-SOMALOGIC PARTNERSHIP

EVENT 2: Friday January 29<sup>th</sup> 2016 - 9am-1pm

KENNEDY INSTITUTE SEMINAR ROOM

## APPLYING LARGE-SCALE PROTEOMICS TOWARDS MORE COST-EFFECTIVE HEALTH CARE IN THE U.K.

Chairs: **Marc Feldmann** and **Simon Lovestone**

### INTRODUCTORY TALKS

**1 John Bell**

**2 Rory Collins** (UK Biobank & Oxford)

UK Biobank: an open-access resource for large-scale epidemiological research

**3 John Danesh** (Cambridge )

### PANEL DISCUSSIONS

**1 How to implement and use SOMAscan data for improvements of healthcare in specific domains**

- **A challenge: What are the top issues in UK NHS Healthcare, and how can improved molecular health information / stratification improve care outcomes and costs: Problem-Solution Format – PRESENTED AND MODERATED BY ? BELINDA QUINN**
- **How clinical innovation can be developed and piloted using SOMAscan within the NHS;**

**SPECIFIC EXAMPLAR: Improving Management of Cardiovascular Disease and Diabetes Through Better Stratification of Major Event Risk [presentation by Steve Williams describing the data and Oxford colleagues (Katharine Owen, Keith Channon, Mark McCarthy, Nick Scott-Ram discussing the clinical implementation program]**

## 2 PANEL/OPEN DISCUSSION – APPLYING THIS IN OTHER FIELDS

- Tumour profiling and Blood-Based Monitoring for Improved Cancer Care
- Understanding and managing dementia
- Phenotyping patients for Faster, smaller, More Effective Clinical Trials

From Somalogic:

<b>Steve Williams</b>	Chief Medical Officer
<b>Larry Gold</b>	Founder, Chairman of the Board of Directors
<b>Mark Messenbaugh</b>	Exec Director, Corporate Strategy & Development
<b>Byron Hewett</b>	Chief Executive Officer

POSSIBLE ATTENDEES (not in order)

**Richard Barker**, **John McKinley**, **Belinda Quinn** (NHS Precision Medicine Catapult)

**John Danesh**, **Nick Wareham**, **Claudia Langenberg** (Cambridge)  
**Aroon Hingorani & Juan-P Casas** (UCL)

**Richard Dobson** (Kings)

Oxford AHSN:

**Nick Scott-Ram**

**Julie Hart**

**Gary Ford**

**Sian Rees**

Oxford: **Paul Klenerman** (can't do Friday), **Keith Channon**, **Katharine Owen**, **Mark McCarthy**, **Rury Holman**, **Philippa Hulley**, **Maxine Allen**, others who are initiating studies within Oxford

**Peter Katsikis** (Erasmus)